Drug
AV 299
AV 299: highest development phase Phase 1, developed by Aveo Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Aveo Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| AV-299 NCT00725634 | Phase 1 | Malignant Solid Tumor |
| AV-299 NCT00969410 | Phase 1 | Malignant Solid Tumour |
Latest
No recent events.
Follow AV 299 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.